ProMIS Neurosciences Inc..
PMN.US | Research and experimental development on natural sciences and engineering
ProMIS Neurosciences Inc. is a biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinso...Show More
Better Health for All
40
ProMIS Neurosciences' entire business is dedicated to discovering and developing antibody therapeutics for severe neurodegenerative diseases like Alzheimer's, ALS, and Parkinson's, aiming to provide revolutionary health benefits. The company is currently in the research and development phase and has no revenue from products with established negative health outcomes.
1
Research and development expenses significantly increased to $5.5 million in Q1 2025, up from $2.1 million in Q1 2024, primarily due to costs associated with the PMN310 Phase 1b clinical trial.
2
The company's clinical trials, such as the PRECISE-AD trial for PMN310, are designed as randomized, double-blind, placebo-controlled studies, indicating adherence to ethical clinical trial practices.
3
Fair Money & Economic Opportunity
0
No evidence available to assess ProMIS Neurosciences Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess ProMIS Neurosciences Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles primarily focus on financial performance, drug development, and regulatory compliance (GLP, GCP, cGMP) for a biotechnology company. Statements like 'The document does not report any incidents' are considered an absence of data regarding the company's actual performance on a KPI, rather than a direct factual statement about the company's operations, and therefore do not constitute scorable evidence.
Honest & Fair Business
0
No evidence available to assess ProMIS Neurosciences Inc. on Honest & Fair Business.
Kind to Animals
-60
The company utilizes in silico discovery, computational algorithms, and in vitro functional assays for target identification and early-stage antibody validation before proceeding to animal models.
1
However, preclinical testing of human therapeutics is conducted on animals, including mice, transgenic mouse models, and Cynomolgus monkeys, to evaluate efficacy, safety, and toxicity.
2
The company's policy is not explicitly stated as prohibiting or significantly restricting animal testing, with routine non-essential testing appearing to continue. Animal usage includes 12 mice per group in one study, 17 mice per group in another, 4-6 mice per time point in a kinetics study, 8 Cynomolgus monkeys in a toxicology study, and 5-6 Balb/c mice per group in vaccination studies.
3
While the company's R&D platform is based on computational power and AI, less than 1% of its R&D spending supports the development of non-animal methods.
4
The company participates in collaborative research with the University of British Columbia, which received a research grant from the Weston Family Foundation for early work on a Parkinson's vaccine.
5
No War, No Weapons
0
ProMIS Neurosciences Inc. is a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases. The provided articles, including a financing announcement, explicitly state that they do not contain data related to the company's involvement in the arms industry or peacebuilding initiatives.
1
There is no evidence of any defense or arms-related activities, dual-use technologies, sales to embargoed regimes, or any other activities relevant to the 'No War, No Weapons' value.
2
Therefore, all KPIs are scored as N/A, indicating no applicability to the company's core business based on the available information.
Planet-Friendly Business
-20
The company reported no specific environmental compliance violations in its fiscal year 2022 filing.
1
Respect for Cultures & Communities
0
The provided articles, which include SEC filings, financial press releases, and a summary of governance documents, do not contain any specific, concrete data points related to PMN.US's respect for cultures and communities. Therefore, no KPIs under this ethical value can be scored based on the evidence provided.
Safe & Smart Tech
0
No data relevant to Safe & Smart Tech or any of the requested metrics was found in the provided articles. One article was a press release announcing a presentation.
1
The other was an SEC filing that could not be accessed due to throttling, preventing data extraction.
2
Zero Waste & Sustainable Products
0
No specific, concrete data points or metrics related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education for PMN.US were found in the provided article.
1